Efdamrofusp alfa

Efdamrofusp alfa is a bispecific fusion protein. Efdamrofusp alfa is capable of neutralizing both VEGF isoforms and C3b/C4b. Efdamrofusp alfa can be used for the research of neovascular age-related macular degeneration (nAMD) and other complement-related ocular conditions[1].

Research Areas >> Cardiovascular Disease

Signaling Pathways >> Protein Tyrosine Kinase/RTK >> VEGFR

Research Areas >> Neurological Disease

Efdamrofusp alfa（0.135 mg/mL；0、6、12 或 24 小时）抑制内皮细胞迁移和管形成[1]。 Efdamrofusp alfa (0-1000 μg/mL) 在体外抑制补体激活[1]。 Cell Migration Assay [1] Cell Line: Human primary umbilical vein endothelial cell (HUVEC) Concentration: 0.135 mg/mL Incubation Time: 0, 6, 12, or 24 h Result: Showed a 20.91% reduction in migration.

Efdamrofusp alfa（13.5 μg；3 天）在激光诱导的 CNV 小鼠模型中抑制补体系统的激活[1]。 Efdamrofusp alfa（1.35 mg；单次玻璃体内注射）在非人灵长类动物激光诱导的 CNV 模型中显示出良好的安全性和抗血管生成功效[1]。 Animal Model: C57BL/6J mice[1] Dosage: 13.5 μg; 13.0 μg Administration: 3 days; 7days Result: Significantly reduced C3d deposition. Reduced vascular leakage at 7 days after laser-induced injury. Significantly suppressed CNV formation 7 days after laser-induced injury. Reduced the concentrations of vitreous VEGF-A. Animal Model: Rhesus monkeys[1] Dosage: 1.35 mg Administration: Single intravitreal injection Result: Decreased the CNV leakage at 14 and 28 days and effectively reduced CNV volume 28 days.

[1]. Shiqi Yang, et al. Targeting C3b/C4b and VEGF with a bispecific fusion protein optimized for neovascular age-related macular degeneration therapy. Sci Transl Med. 2022 Jun;14(647):eabj2177.